Sign In
Media release
From:
Attachments
Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.
Novavax reports 90.4% efficacy against COVID-19 infection
Publicly released:
International
The Novavax vaccine is 90.4 per cent effective at preventing COVID-19 infection, according to the company's phase 3 trial. Novavax gave at least one dose of the vaccine to nearly 20,000 people, with about 10,000 receiving a placebo (sugar pill). Over three months, 14 vaccinated participants tested positive to COVID-19 and 77 placebo participants tested positive. Ten moderate and four severe cases occurred, all in the placebo group. Of the COVID-19 cases that were sequenced, four in five were a variant of interest or variant of concern.
Media Contact/s 
Contact details are only visible to registered journalists.
Share this page
More News
Immune system dysfunction may explain why chronic illness and depression often go hand in hand
Australia; VIC
The University of Melbourne,La Trobe University
Nature Mental Health
Combination immunotherapy shows improved efficacy and survival rates in rare cancer study
Australia; New Zealand; NSW; VIC; QLD; SA; WA; TAS
La Trobe University,Olivia Newton-John Cancer Research Institute...
JAMA Oncology
Do e-cigarettes compromise children's human rights?
Australia; International; ACT
The Australian National University,University of Bath...
The BMJ